Liquidia (LQDA) Change in Receivables (2021 - 2026)
Liquidia's (LQDA) quarterly Change in Receivables came in at $20.1 million in Q1 2026, up 1463.04% year-on-year from $1.3 million in Q1 2025, and up 10.64% quarter-over-quarter from $18.1 million in Q4 2025.
Liquidia (LQDA) Change in Receivables (2021 - 2026) Analysis & Trends
Liquidia's Change in Receivables history runs 6 years deep, the most recent figure standing at $20.1 million for Q1 2026.
- On a quarterly basis, Change in Receivables rose 1463.04% year-over-year to $20.1 million in Q1 2026; TTM through Mar 2026 was $72.9 million, a 5610.96% increase from a year earlier, with the FY2025 full-year figure at $51.4 million, up 3928.17% from the prior year.
- Change in Receivables climbed to $20.1 million in Q1 2026 per LQDA's latest filing, from $18.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $26.0 million in Q3 2025 and bottomed at -$1.5 million in Q1 2024.
- The 5-year median for Change in Receivables is $466000.0 (2022), against an average of $4.2 million.
- Biggest YoY gain for Change in Receivables was 3235.0% in 2022; the steepest drop was 1163.79% in 2022.
- Year by year, Change in Receivables stood at $1.9 million in 2022, then plunged by 61.56% to $723000.0 in 2023, then sank by 305.12% to -$1.5 million in 2024, then jumped by 1322.79% to $18.1 million in 2025, then gained by 10.64% to $20.1 million in 2026.
- Per Business Quant, the three latest LQDA Change in Receivables figures stand at $20.1 million (Q1 2026), $18.1 million (Q4 2025), and $26.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 20.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.06 Mn |
| Mar 31, 2026 | 20.06 Mn |
| Dec 31, 2025 | 18.13 Mn |
| Dec 31, 2025 | 18.13 Mn |
| Sep 30, 2025 | 25.99 Mn |
| Sep 30, 2025 | 25.99 Mn |
| Jun 30, 2025 | 8.72 Mn |
| Jun 30, 2025 | 8.72 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | -1.48 Mn |
| Dec 31, 2024 | -1.48 Mn |
| Sep 30, 2024 | 953,000.00 |
| Sep 30, 2024 | 953,000.00 |
| Jun 30, 2024 | 679,000.00 |
| Jun 30, 2024 | 679,000.00 |
| Mar 31, 2024 | -1.49 Mn |
| Mar 31, 2024 | -1.49 Mn |
| Dec 31, 2023 | 723,000.00 |
| Dec 31, 2023 | 723,000.00 |